Medix Biochemica Appoints Dr. Michele Pedrocchi, Former Head of Business Development for Roche Diagnostics, to its Board of Directors1st Sep 2022
Medix Biochemica announces the appointment Dr. Michele Pedrocchi, former Global Head of Strategy and Business Development for Diagnostics at Roche, to its Board of Directors. Dr. Pedrocchi brings 25 years of international experience in in-vitro diagnostics, digital health, life sciences and personalized medicine.
Bioresource Technology joins Medix Biochemica Group20th Jun 2022
Medix Biochemica has acquired USA-based Bioresource Technology Inc., a leading provider of base matrices for the in vitro diagnostics manufacturing industry worldwide
Medix Biochemica launches refreshed and expanding brand1st Mar 2022
Medix Biochemica is launching a rejuvenated brand to reflect both the exciting improvements to its offering as a result of recent acquisitions, and its ongoing commitment to the in vitro diagnostics (IVD) industry.
Medix Biochemica acquires myPOLS Biotec1st Feb 2022
Medix Biochemica has acquired 100 percent of the shares of myPOLS Biotec GmbH, a German manufacturer of innovative and high-quality raw materials in molecular diagnostics.
Delivering IVD raw material expertise in China for 5 years16th Nov 2021
This year marks the fifth anniversary of Medix Biochemica in China. Over the past five years, Medix Biochemica China, and China’s IVD industry have undergone significant changes and developments.
Discover new study findings of Serum Amyloid A mAbs30th Sep 2021
Medix Biochemica presented the findings of a study ‘Monoclonal Serum Amyloid A antibodies applicable to human and veterinary diagnostic immunoassays with wide detection ranges’ in 2021 AACC exhibition in Atlanta, on September 28th.